Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicate… This content is
This is mainly useful for risk communication, vaccination advice, and infection-related patient counselling.
ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.